The HAS-BLED tool demonstrated some diagnostic ability to predict major bleeding in atrial fibrillation patients receiving rivaroxaban, though this was not statistically significant.
Does the HAS-BLED tool predict major bleeding events in atrial fibrillation patients receiving rivaroxaban?
The HAS-BLED tool showed a non-significant trend in predicting major bleeding in AF patients on rivaroxaban, limited by a small sample size.
Absolute Event Rate: 0% vs 0%
HAS-BLED demonstrated some diagnostic ability to predict major bleeding events in patients receiving rivaroxaban but this was not statistically significant due to limited sample size.
Gorman et al. (Wed,) reported a other. The HAS-BLED tool demonstrated some diagnostic ability to predict major bleeding in atrial fibrillation patients receiving rivaroxaban, though this was not statistically significant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: